Version 1
: Received: 4 January 2024 / Approved: 4 January 2024 / Online: 4 January 2024 (11:35:28 CET)
Version 2
: Received: 8 January 2024 / Approved: 8 January 2024 / Online: 9 January 2024 (14:48:40 CET)
Hsu, Y.-F.; Lin, S.-P.; Chu, Y.-T.; Tsai, Y.-T.; Huang, J.-W.; Phoa, F.K.H.; Wu, R.-M. Plasma miR-203a-3p as a Novel Predictor of Dementia in Patients with Parkinson’s Disease. Int. J. Mol. Sci.2024, 25, 3554.
Hsu, Y.-F.; Lin, S.-P.; Chu, Y.-T.; Tsai, Y.-T.; Huang, J.-W.; Phoa, F.K.H.; Wu, R.-M. Plasma miR-203a-3p as a Novel Predictor of Dementia in Patients with Parkinson’s Disease. Int. J. Mol. Sci. 2024, 25, 3554.
Hsu, Y.-F.; Lin, S.-P.; Chu, Y.-T.; Tsai, Y.-T.; Huang, J.-W.; Phoa, F.K.H.; Wu, R.-M. Plasma miR-203a-3p as a Novel Predictor of Dementia in Patients with Parkinson’s Disease. Int. J. Mol. Sci.2024, 25, 3554.
Hsu, Y.-F.; Lin, S.-P.; Chu, Y.-T.; Tsai, Y.-T.; Huang, J.-W.; Phoa, F.K.H.; Wu, R.-M. Plasma miR-203a-3p as a Novel Predictor of Dementia in Patients with Parkinson’s Disease. Int. J. Mol. Sci. 2024, 25, 3554.
Abstract
The early detection of cognitive decline and timely non-pharmacological management or drug therapy are extremely important in providing care for Parkinson’s disease with dementia (PDD). In this study, we first conducted a discovery study to identify six plasma microRNAs that may allow for the differentiation of PD with or without mild cognitive impairment via NGS. A total of 120 participants were further recruited in a validation cohort and divided into four subgroups, namely, normal controls (HC), PD with no dementia (PDND), PD with mild cognitive impairment (PD-MCI) and PDD. Among the six candidates, miR-203a-3p was successfully detected in the plasma of the validation cohort using droplet digital PCR (ddPCR). Our results show that the ratio of miR-203a-3p/miR-16-5p observed in PDD was significantly increased compared to in PD-MCI (p < 0.001) and PDND (p = 0.041). Moreover, the ratio of miR-203a-3p/miR-16-5p showed a significant correlation with MoCA scores (r = -0.237, p = 0.024) in patients with PD (PwP). The ROC curve of the logistic regression model, consisting of the variables of age, the ratio of miR-203a-3p/miR-16-5p and the UPDRS III score, also demonstrated an average AUC of 0.883 via 5-fold cross-validation. In conclusion, the ratio of miR-203a-3p/miR-16-5p may serve as a potential biomarker for distinguishing cognitive dysfunction from PwP.
Keywords
Plasma Biomarker; MicroRNA; Parkinson’s Disease; Cognitive decline; Droplet digital PCR
Subject
Biology and Life Sciences, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Commenter: Ruey-Meei Wu
Commenter's Conflict of Interests: Author